Patents Issued in September 15, 2016
-
Publication number: 20160262998Abstract: The invention relates to styling agents, comprising—with respect to the weight thereof—0.1 to 20 wt % of strengthening polymer(s) and 0.1 to 5 wt % of esters of the formula (I), in which R1 stands for —H or CH3, R2 stands for a straight-chain or branched alkyl group having 7 to 15 carbon atoms, and n stands for an integer from the group 1, 2, 3, 4, 5, 6, 7, 8. Said styling agents effect significantly improved curl retention, in particular significantly improved high-humidity curl retention, thus a higher degree of curl retention even in a humid environment in addition to further improved hold and improved hair feel, such as texture and combability.Type: ApplicationFiled: May 24, 2016Publication date: September 15, 2016Applicant: Henkel AG & Co. KGaAInventors: Diane Metten, Julia Bibiane Lange, Bernd Richters
-
Publication number: 20160262999Abstract: The antimicrobial composition of the present invention comprises a cationic active ingredient, a foam boosting surfactant, a foam boosting copolymer, a foam stabilizer, and a chelating agent. The present antimicrobial compositions are free of the antimicrobial agent triclosan (i.e., 2,4,4?-trichloro-2?hydroxy-diphenylether), have rapid cidal activity, provide stable copious foam and exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.Type: ApplicationFiled: May 20, 2016Publication date: September 15, 2016Inventors: Daniel E. Pedersen, Carter M. Silvernail, Kerrie E. Walters, Hilina Emiru
-
Publication number: 20160263000Abstract: Methods for styling, in particular for straightening, keratin fibers, in particular human hair, in which (i) a styling agent comprising carbocisteine and/or a salt thereof is applied to the keratin fibers and left there, (ii) the fibers, after a leave-in time, —are not rinsed, —are optionally dried, (iii) the fibers are mechanically deformed from exposure to heat, significantly minimize the negative consequences of styling and reduce in particular electrostatic charging and hydrophilization of the hair.Type: ApplicationFiled: May 26, 2016Publication date: September 15, 2016Applicant: Henkel AG & Co. KGaAInventors: Birgit Rautenberg-Groth, Stephan Schwartz, Katharina Krause
-
Publication number: 20160263001Abstract: The subject matter of the present invention provides a composition for oxidatively coloring keratinic fibers, comprising, in a cosmetic carrier (A) as developer, 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or a physiologically acceptable salt thereof, (B) as developer, at least one p-aminophenol derivative from the group of p-aminophenol, 4-amino-3-methylphenol and/or a physiologically acceptable salt thereof, (C) as coupler at least one m-diaminobenzene derivative from the group 2-(2,4-diaminophenoxy)ethanol, 1-methoxy-2-amino-4-(2?-hydroxyethylamino)benzene and/or a physiologically acceptable salt thereof, (D) as coupler at least one m-dihydroxybenzene derivative from the group of resorcinol, 2-methylresorcinol and/or 4-chlororesorcinol, the molar ratio of all group (A) developers to all group (B) developers in the composition, i.e. the molar ratio (A)/(B), being at least 1.2.Type: ApplicationFiled: May 20, 2016Publication date: September 15, 2016Applicant: Henkel AG & Co. KGaAInventors: Antje Gebert-Schwarzwaelder, Annika Koenen
-
Publication number: 20160263002Abstract: The subject matter of the present invention relates to an agent for oxidatively dyeing keratinous fibers, comprising, in a cosmetic carrier, (A) 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof as a developer, (B) at least one p-diaminobenzene derivative from the group of p-toluylenediamine, 2-(2,5-diaminophenyl)ethanol, and/or one of the physiologically acceptable salts thereof as a developer, (C) at least one m-diaminobenzene derivative from the group of 2-(2,4-diaminophenoxy)ethanol, 1-methoxy-2-amino-4-(2?-hydroxyethylamino)benzene, 2,6-bis(2?-hydroxyethylamino)-1-methylbenzene, and/or one of the physiologically acceptable salts thereof as a coupler, and (D) at least one m-aminophenol derivative from the group 3-aminophenol, 5-amino-2-methylphenol, and/or one of the physiologically acceptable salts thereof as a coupler, wherein the molar ratio of all developers of group (A) included in the agent to all developers of group (B) included in the agent, i.e.Type: ApplicationFiled: May 24, 2016Publication date: September 15, 2016Applicant: Henkel AG & Co. KGaAInventors: Antje Gebert-Schwarzwaelder, Astrid Kroos
-
Publication number: 20160263003Abstract: Compositions, kits, and methods for rebuilding the the disulfide bonds in hair that is damaged due to a hair coloring treatment are disclosed. The compositions contain one or more compounds that covalently crosslink at least two thiol groups in the hair. The compositions may be applied subsequent to a hair coloring treatment or simultaneously with a hair coloring treatment. Under normal hair washing conditions, the covalent crosslinks formed are not succeptable to reduction or hydrolysis. Use of the crosslinking compositions prevent the reversion of the hair's disulfide bonds to its reduced state, for at least one week, preferably at least three months, more preferably at least one year, most preferably at least greater than one year, after at least one application of the composition.Type: ApplicationFiled: October 13, 2015Publication date: September 15, 2016Inventors: Eric D. Pressly, Craig J. Hawker
-
Publication number: 20160263004Abstract: The subject matter of the invention relates to agents for oxidatively dyeing keratinic fibers, comprising, in a cosmetic carrier, (A) 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof as developer, (B) 2-(2,5-diaminophenyl)ethanol and/or one of the physiologically acceptable salts thereof as developer, (C) 2,6-bis(2?-hydroxyethylamino)-1-methylbenzene and/or one of the physiologically acceptable salts thereof as coupler, and (D) at least one m-dihydroxybenzene derivative from the group comprising resorcinol, 2-methylresorcinol, and/or 4-chlororesorcinol as coupler.Type: ApplicationFiled: May 26, 2016Publication date: September 15, 2016Applicant: Henkel AG & Co. KGaAInventors: Antje Gebert-Schwarzwaelder, Annika Koenen
-
Publication number: 20160263005Abstract: Embodiments of the invention are generally directed to compositions useful for reducing histamine-induced pigmentation in the skin. The composition may further include other depigmenting agents such as nicotinamide and its melanasome transfer-inhibiting derivatives, 3,3?-thiodipropanoic acid and its tyrosinase-inhibiting derivatives, or resorcinol and its tyrosinase-inhibiting derivatives, in a cosmetically acceptable vehicle.Type: ApplicationFiled: September 30, 2014Publication date: September 15, 2016Applicant: AVON PRODUCTS, INC.Inventors: Hong Hu, Sunghan Yim, Uma Santhanam, John W. Lyga
-
Publication number: 20160263006Abstract: Embodiments of the invention are generally directed to compositions useful for reducing pigmentation in the skin. The composition may further include other depigmenting agents such as nicotinamide and its melanasome transfer-inhibiting derivatives, 3,3?-thiodipropanoic acid and its tyrosinase-inhibiting derivatives, or resorcinol and its tyrosinase-inhibiting derivatives, in a topically acceptable vehicle.Type: ApplicationFiled: September 30, 2014Publication date: September 15, 2016Inventors: Hong Hu, Sunghan Yim, Uma Santhanam, John W. Lyga
-
Publication number: 20160263007Abstract: The present invention provides a method of treating a tooth surface to control or reduce dentine hypersensitivity, comprising the steps: (a) contacting the tooth surface with a first composition comprising an organophosphate; and thereafter (b) contacting the tooth surface with a second composition comprising a water-insoluble calcium phosphate.Type: ApplicationFiled: May 20, 2016Publication date: September 15, 2016Inventors: Ross STRAND, Alastair Robert Edward MACGREGOR, Claire GOODALL
-
Publication number: 20160263008Abstract: A method for forming a large particle complex comprising the steps of combining a hydrolyzed corn starch polymer, a starch/cellulose polymer, a hydrogenated phospholipid, and gum arabic in a cosmetically acceptable carrier to form a premix composition; heating said premix to about 85° C. for about 15 minutes; and cooling the composition to room temperature. The particle complex is useful as a component of a sprayable composition which provides volumizing, hair fixing, and conditioning as a leave-on treatment for human hair.Type: ApplicationFiled: February 5, 2013Publication date: September 15, 2016Inventors: John Michael Bohen, Amy Christine Anderson-Gaber, Anita Marie Grahn
-
Publication number: 20160263009Abstract: A hair cosmetic composition comprising the following components (A), (B) and water, having a pH of 6 or less, and the component (B) being dispersed in a water phase: (A) an oxyalkylene polymer represented by formula -(AO)n— wherein A represents a C2-6 alkylene group and n represents a number of 50 to 30,000, provided that n pieces of AO comprise at least two alkyleneoxy groups, which are arranged through either random polymerization or block polymerization; and (B) a polymer comprising a constitutional unit represented by the following formula (b1) and a constitutional unit represented by the following formula (b2), having a weight average molecular weight of 5,000 to 1,000,000, and having an acid value of 5 to 400: —(CH2CR1COOH)—??(b1) —(CH2CR2COOR3)—??(b2) wherein R1 and R2 represent H or CH3, and R3 represents a C1-30 hydrocarbon group.Type: ApplicationFiled: November 11, 2014Publication date: September 15, 2016Applicant: KAO CORPORATIONInventors: Hiroaki SAITO, Chie SAKAGUCHI, Kana TSUMURA
-
Publication number: 20160263010Abstract: The present invention relates generally to topical compositions and methods of using the compositions to treat keratin fibers. The compositions, such as mascaras, can form films of low resiliency on the surface of the keratin fibers, which impart moldability to the treated fibers, thereby enhancing the range of styling effects and options available to the user.Type: ApplicationFiled: September 12, 2014Publication date: September 15, 2016Applicant: AVON PRODUCTS, INC.Inventors: Mohannad Abdo, Candice DeLeo Novack, Ashley L. Howell, Jody P. Ebanks
-
Publication number: 20160263011Abstract: The present invention relates to the cosmetic use of an essential oil of Achillea, as an active agent for preventing and/or treating the signs of skin ageing, characterized in that this essential oil of Achillea comprises the following compounds, each present at more than 5% by weight relative to the total weight of the essential oil: artemisia ketone, chrysanthenone (two combined isomers), and ascaridole. It also relates to the associated cosmetic process.Type: ApplicationFiled: October 21, 2014Publication date: September 15, 2016Applicant: L'OREALInventors: Joan EILSTEIN, Corinne FERRARIS
-
Publication number: 20160263012Abstract: A topical composition including an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species is used for improving and/or increasing and/or stimulating and/or promoting and/or inducing the pigmentation of hair and/or hairs.Type: ApplicationFiled: October 15, 2014Publication date: September 15, 2016Applicant: LEGACY HEALTHCARE LTD.Inventor: Saad HARTI
-
Publication number: 20160263013Abstract: The present disclosure provides a mixture of sugar apple and rosemary extracts, optionally in combination with prickly ash extract, for use as skin care compositions.Type: ApplicationFiled: October 30, 2014Publication date: September 15, 2016Applicants: Unigen, Inc., Unigen, Inc.Inventors: Lidia Alfaro Brownell, Min Chu, Brandon Corneliusen, Mei-Feng Hong, Ji-Hye Hwang, Eu-Jin Hyun, Qi Jia, Ping Jiao, Mi-Ran Kim, Bo-Su Lee, Young-Chul Lee, Jeong-Bum Nam, Mi-Sun Oh, Mesfin Yimam
-
Publication number: 20160263014Abstract: Exopolysaccharide of a bacterial strain for its use in treatment and/or care of the skin, as well as its cosmetic and/or dermopharmaceutical compositions. In particular, its use for inflammation, lipolysis, lipid accumulation and skin firmness.Type: ApplicationFiled: October 30, 2014Publication date: September 15, 2016Inventors: Núria García Sanz, Antonio Vicente Ferrer Montiel, Albert Soley Astals, Nuria Almiñana Doménech
-
Publication number: 20160263015Abstract: The present invention relates to a single-layer, effervescent tablet comprising a high level of aspirin and a reduced amount of alkaline substances, where the tablet rapidly dissolves in water.Type: ApplicationFiled: October 23, 2014Publication date: September 15, 2016Inventors: Foyeke OPAWALE, Priya NAYAK, Gerard MEISEL
-
Publication number: 20160263016Abstract: In one aspect, an ingestible, electrical device, comprises a substrate comprising a reservoir that is configured to hold one or more substances; a first film covering the reservoir, wherein the first film is at least partially metallic; a charge storage system connected to the first film, the charge storage system configured to deliver a transient electrochemical potential to the first film; wherein the first film is configured to prevent exposure of the substance to an aqueous environment in an organism, while the charge storage system delivers the transient electrochemical potential to the first film; and wherein the first film is configured for dissolution to expose the one or more substances to the aqueous environment in the organism, after the charge storage system stops delivering the transient electrochemical potential to the first film.Type: ApplicationFiled: October 23, 2014Publication date: September 15, 2016Inventor: Christopher J. BETTINGER
-
Publication number: 20160263017Abstract: Embodiments of the disclosure provide methods and/or compositions useful for an individual in need of treatment of a cardiac-related medical condition. In particular cases, GLP-1 is employed in a ultrasound targeted microbubble destruction (UTMD) system for delivery to cardiac tissue, thereby stimulating myocardial regeneration and, in at least some cases, reversal of cardiomyopathy.Type: ApplicationFiled: November 7, 2014Publication date: September 15, 2016Inventors: Paul A. Grayburn, Shuyuan Chen
-
Publication number: 20160263018Abstract: The present invention relates to a method for treating symptoms from a nicotine withdrawal comprising administering to a patient an effective amount of a transdermal compound. In one embodiment the compound includes the following active ingredients: Sertraline, Imipramine, Topiramate, and Bupropion, while in another embodiment the active ingredients are: Fluoxetine, Nortriptyline, Topiramate, and Bupropion.Type: ApplicationFiled: March 12, 2015Publication date: September 15, 2016Applicant: Trinity Pharma GroupInventors: Kruitka Patel, Devan Patel
-
Publication number: 20160263019Abstract: Compositions and methods for treating inflamed skin with Pro-Resolution Pathway Stimulators that may be Inflammatory Metabolite Inhibitors, Pro-Resolving Activators, or combinations thereof, and a method for screening active ingredients for activity as Pro-Resolution Pathway Stimulators for incorporation into topical cosmetic products.Type: ApplicationFiled: February 26, 2016Publication date: September 15, 2016Inventors: Nadine A. Pernodet, Donald F. Collins, Fatemeh Mohammadi
-
Publication number: 20160263020Abstract: The present application provides methods of administering an IL-22 dimer to an individual, such as a human individual, comprising intravenously administering to the individual an effective amount of an IL-22 dimer, wherein the amount of the IL-22 dimer is about 2 ?g/kg to about 200 ?g/kg (such as about 10 ?g/kg to about 45 ?/kg), as well as methods of treating diseases by following such administration methods. Also provided are kits, unit dosages, and articles of manufacture for use in any one of the methods described herein.Type: ApplicationFiled: November 6, 2014Publication date: September 15, 2016Inventors: Xiaoqiang YAN, Cheng HUANG, Dongdong WU, Kaiyang TANG, Yuliang HUANG
-
Publication number: 20160263021Abstract: A method for preventing or treating tetanus infection in a subject, comprising administering a non-adjuvanted tetanus toxoid vaccine to the skin. The vaccine can be delivered by intradermal injection or microneedle patch and does not require cold storage.Type: ApplicationFiled: March 10, 2016Publication date: September 15, 2016Inventors: Ioanna Skountzou, E. Stein Esser, Richard Compans, Shaguna Seth
-
Publication number: 20160263022Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: ApplicationFiled: December 6, 2013Publication date: September 15, 2016Inventor: Patrick M. Hughes
-
Publication number: 20160263023Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.Type: ApplicationFiled: October 14, 2014Publication date: September 15, 2016Applicant: PHARMATHEN S.A.Inventors: EVANGELOS KARAVAS, EFTHIMIOS KOUTRIS, VASILIKI SAMARA, IOANNA KOUTRI, ANASTASIA KALASKANI, ANDREAS KAKOURIS, GEORGE GOTZAMANIS
-
Publication number: 20160263024Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.Type: ApplicationFiled: March 10, 2016Publication date: September 15, 2016Inventors: Mike Jaffe, Gary Cook, Perry Calias, Michael A. Patane
-
Publication number: 20160263025Abstract: A neuromuscular aid for alleviation and prevention of conditions including muscle cramps and spasms. The neuromuscular aid may be in the form of a packet including a composition including 1 wt% to 15 wt% food grade acid. Instructions for use printed on an exterior of the packet include instructions to retain the composition in the oral cavity of a user for a length of time to alleviate or prevent muscle cramps. An oral treatment method includes administering a composition including 1 wt% to 15 wt% food grade acid to the oral cavity of a subject suffering from muscle cramps and retaining the composition in the oral cavity for a length of time. The composition may be in the form of a gas, a liquid, a solid, a gum, a powder, a thin film strip, a suspension, a colloid, or a gel.Type: ApplicationFiled: March 10, 2016Publication date: September 15, 2016Inventors: Jack E. Little, David Clarke
-
Publication number: 20160263026Abstract: An oral thin film for inhibiting the progression of macular degeneration, having as active ingredients a zinc compound, lutein, or zeaxanthin, or a combination thereof, contained in an ingestible oral thin film. The oral thin film is placed in the mouth of a user and allowed to dissolve therein. The zinc compound, lutein, or zeaxanthin, or a combination thereof, is ingested in a liquid form by the user after the oral thin film dissolves. The active ingredients are delivered to the gastrointestinal tract of the user where they are absorbed into the systemic circulation. The zinc compound may be microencapsulated to prevent the metallic taste of the zinc compound.Type: ApplicationFiled: November 12, 2014Publication date: September 15, 2016Inventors: Jeffery MCANNALLY, John O. MASON, III
-
Publication number: 20160263027Abstract: Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of inflammatory and/or obstructive airways diseases.Type: ApplicationFiled: May 20, 2016Publication date: September 15, 2016Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Irene PASQUALI, Rossella Musa, Francesca Schiaretti, Azita Askey-Sarvar
-
Publication number: 20160263028Abstract: An avian tincture composition and associated methods for producing the same for treatment of the avian species with the avian tincture. The avian tincture may be used in the treatment of abscesses, inflamed and swollen leg joints, respiratory issues, wounds, infection, and acute disease or parasite overload conditions.Type: ApplicationFiled: March 10, 2016Publication date: September 15, 2016Inventor: Susan Burek
-
Publication number: 20160263029Abstract: A topical pharmaceutical gel compositions of diclofenac sodium, is provided. The topical gel composition contains at least about 10% w/w diclofenac sodium and is suitable for twice daily application.Type: ApplicationFiled: February 29, 2016Publication date: September 15, 2016Applicant: Gavis PharmaceuticalsInventor: Bala Chandran Nayar
-
Publication number: 20160263030Abstract: One aspect of the disclosure relates to a new fom1 of lipid-complexed active platinum compound, which allows for high concentrations of platinum compound in the composition. For example, the concentration of cisplatin in the composition is higher at room temperature, e.g., about greater than 1.2 mg/mL, compared to 1 mg/mL in aqueous solution. In one embodiment, the present invention is directed to a composition comprising a lipid-complexed active platinum compound, wherein the complex has a lipid to drug (L/D) ratio of less than about 1 by weight, e.g. about 0.10 to 1, wherein the lipid-complexed active platinum compound comprises at least one lipid and at least one active platinum compound. In other embodiments, wherein lipid-complexed active platinum compound has an average volume-weighted diameter of about 0.5 to about 20 microns. In still other embodiments, the composition further comprises a liposome.Type: ApplicationFiled: October 12, 2015Publication date: September 15, 2016Inventors: Jin K. Lee, Brian S. Miller, Fangjun WU, Lawrence T. BONI, Vladimir MALININ
-
Publication number: 20160263031Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.Type: ApplicationFiled: October 22, 2014Publication date: September 15, 2016Inventors: Jonathan H. Kaufmann, Michael B. Chancellor
-
Publication number: 20160263032Abstract: A method for the preparation of a powdery pharmaceutical composition comprising a pharmaceutical excipient and a pharmaceutical component, wherein the pharmaceutical excipient is a polyalkylene glycol, the method comprising the step of grinding a mixture of the pharmaceutical excipient and the pharmaceutical component at a temperature below ambient temperature.Type: ApplicationFiled: May 25, 2016Publication date: September 15, 2016Applicant: GRUNENTHAL GMBHInventors: Alessandro GRASSANO, Anna PERACHIOTTI, Matteo MINELLI, Daniele VOLPI
-
Publication number: 20160263033Abstract: The invention relates to nutritional compositions comprising specifically designed lipid globules that are especially suited for preterm infants, small for gestational age infants and infants with retarded growth due to physical or mental stress after birth, for promoting catch-up growth and/or for use in improving body composition, improving adipose tissue distribution, decreasing visceral adipose tissue based on body weight and/or on total adipose tissue, and/or decreasing the ratio visceral adipose tissue to subcutaneous adipose tissue, in such infants, and/or providing nutrition to such infants.Type: ApplicationFiled: November 3, 2014Publication date: September 15, 2016Applicant: N.V. NutriciaInventors: Eline Marleen VAN DER BEEK, Marieke ABRAHAMSE-BERKEVELD, Inga Christiane TELLER
-
Publication number: 20160263034Abstract: The invention concerns an emulsion-based method for the manufacture of a crystalized spherical agglomerate and/or a pharmaceutical product; and crystalized spherical agglomerate and/or a pharmaceutical product manufactured thereby.Type: ApplicationFiled: October 15, 2014Publication date: September 15, 2016Inventors: Saif A. KHAN, Reno Antony Louis LEON, Abu Zayed Md. BADRUDDOZA, Wai Yew WAN, T. Alan HATTON
-
Publication number: 20160263035Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: May 23, 2016Publication date: September 15, 2016Applicant: Endo Pharmaceuticals Inc.Inventors: Anand R. BAICHWAL, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler, David Verbel, Stanley Au
-
Publication number: 20160263036Abstract: The present invention relates to solid dispersions including, but not limited to, co-processed carbohydrates with different solubilities and concentrations, which have a microcrystalline plate structure. The solid dispersions, excipient systems and formulations of the present invention are highly compactable and durable and when compressed into solid dosage forms demonstrate uniform densification, low friability at low pressures, and and/or relatively constant low disintegration times at various hardnesses. The solid dosage forms of the present invention demonstrate superior organoleptics, disintegration, and/or robustness.Type: ApplicationFiled: May 25, 2016Publication date: September 15, 2016Applicant: SPI Pharma, Inc.Inventors: John Tillotson, Cecil Propst
-
Publication number: 20160263037Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.Type: ApplicationFiled: April 19, 2016Publication date: September 15, 2016Applicant: GRÜNENTHAL GMBHInventors: Elisabeth ARKENAU MARIC, Johannes BARTHOLOMAEUS, Heinrich KUGELMANN
-
Publication number: 20160263038Abstract: The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymerType: ApplicationFiled: October 22, 2015Publication date: September 15, 2016Inventors: Masayoshi Fukushima, Kazuhiro Orita, Shogo Yamane
-
Publication number: 20160263039Abstract: A tablet is provided that has a shape parameter that may securely inhibit defects in a manufacturing procedure in an actual production scale based on an analysis corresponding to the type of defect. A tablet 2 is provided that includes: a body 4; and a cup 6 convexly formed from at least one surface of upper and lower surfaces of the body 4, wherein, in a case that a cup depth as a height dimension of the cup 6 is D and a diameter of the body 4 is L, a value of D/L is not less than 0.13 and not more than 0.50.Type: ApplicationFiled: November 11, 2014Publication date: September 15, 2016Inventors: Shuichi Tanabe, Hiroshi Nishino
-
Publication number: 20160263040Abstract: A composite formulation is provided which includes: tadalafil or a pharmaceutically acceptable salt thereof as an active ingredient; and amlodipine or a pharmaceutically acceptable salt thereof as an active ingredient, wherein a total amount of tadalafil and amlodipine is in a range of about 6 parts to about 16 parts by weight based on 100 parts by weight of a total weight of the composite formulation.Type: ApplicationFiled: November 6, 2014Publication date: September 15, 2016Inventors: Jin Cheul KIM, Jae Ho KIM, Caleb Hyungmin PARK, Yong Il KIM, Jae Hyun PARK, Jong Soo WOO
-
Publication number: 20160263041Abstract: A method for manufacturing a compound danshen dripping pill is disclosed. The method comprises: mixing powders of active substances with an excipient in a weight ratio between 1:1 and 1:2 to obtain a mixture; indirectly melting the mixture via a first oil at 75-80° C. until the mixture becomes a molten state; and dripping the melted mixture into a second oil at 3-10° C., cooling and solidifying the melted mixture to obtain the dripping pill. The powders of active substances comprise powders of Chinese salvia, powders of notoginseng and borneol, while the excipient comprises PEG 1500 and PEG 4000 in a weight ratio between 1:1 and 1:3.Type: ApplicationFiled: March 13, 2015Publication date: September 15, 2016Inventor: Po-Lun WANG
-
Publication number: 20160263042Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.Type: ApplicationFiled: May 24, 2016Publication date: September 15, 2016Applicant: Supernus Pharmaceuticals, Inc.Inventors: Argaw Kidane, Padmanabh P Bhatt
-
Publication number: 20160263043Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.Type: ApplicationFiled: February 19, 2016Publication date: September 15, 2016Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
-
Publication number: 20160263044Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: ApplicationFiled: May 24, 2016Publication date: September 15, 2016Inventors: Bret Berner, Sui Yuen Eddie Hou
-
Publication number: 20160263045Abstract: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in gastric fluid, wherein the dosage form is weight biased such that one end is heavier than the other end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the fluid with its heavier end pointing generally downwards and into the fluid.Type: ApplicationFiled: March 17, 2016Publication date: September 15, 2016Inventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
-
Publication number: 20160263046Abstract: The present invention provided for a novel process of forming silk fibroin gels, and controlling the rate of ?-sheet formation and resulting hydrogelation kinetics, by vortex treatment of silk fibroin solution. In addition, the vortex treatment of the present invention provides a silk fibroin gel that may be reversibly shear-thinned, enabling the use of these approach for precise control of silk self-assembly, both spatially and temporally. Active agents, including biological materials, viable cells or therapeutic agents, can be encapsulated in the hydrogels formed from the processes, and be used as delivery vehicles. Hence, the present invention provide for methods for silk fibroin gelation that are useful for biotechnological applications such as encapsulation and delivery of active agents, cells, and bioactive molecules.Type: ApplicationFiled: February 12, 2016Publication date: September 15, 2016Inventors: David L. Kaplan, Tuna Yucel
-
Publication number: 20160263047Abstract: Novel process and products thereby emplace nutraceutical factors within nanodelivery vehicles for various indications in mammals, including humans.Type: ApplicationFiled: October 14, 2014Publication date: September 15, 2016Applicant: Nanaspehre Health Sciences, LLCInventor: Richard Clark Kaufman